Matt Marcus's questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q4 2024
Question
Matt Marcus of Jefferies, on for Andrew Tsai, inquired about the minimum efficacy threshold for Azetukalner to achieve best-in-class status in focal epilepsy and asked about the expected granularity of the upcoming Phase II MDD data from the Mount Sinai study.
Answer
President and CEO Ian Mortimer explained that for the Phase III epilepsy study, the primary goal is achieving statistical significance to support an NDA filing, emphasizing the drug's overall strong profile. Regarding the investigator-sponsored MDD study, he expects to publicly share data on the primary functional MRI endpoint and key secondary clinical scales like MADRS and SHAPS in the first half of 2025.